ADC, precision and deep cultivation for targeted drug delivery

Antibody conjugate (ADC) is the focus of tumor therapy research in recent years. Because of its good targeting and obvious clinical efficacy, ADC has become the frontier of antibody drug research and development and is one of the strategic focuses of new drug research and development in China.

Medicilon has a professional technical team and rich project research experience in preclinical research of ADC and can provide customers with a complete set of preclinical services. The composition of ADC is relatively complex. To reduce the risk of R&D, Medicilon has the responsibility and hopes to have the opportunity to work with colleagues in the pharmaceutical industry to promote the development of targeted therapeutic drugs.

In 1906, the concept of "Magic Bullet" targeted therapy was first proposed;

In 1967, the ADC concept was first proposed;

In 1972, animal experiments were carried out with non-covalently coupled ADCs;

In 1975, animal experiments were carried out with covalently coupled ADCs;

In 1983, the first ADC drug was in clinical trials;

In 1993, the BR96-Doxorubicin conjugate (BMS-182248) achieved cure in a human tumor xenograft mouse model;

In 2009, Mylotarg (Pfizer) became the first approved ADC drug;

In 2010, Mylotarg was withdrawn from the US market;

In 2011, Adcetris (Takeda) was approved by the FDA;

In 2013, Kadcyla (Roche) was approved by the FDA;

In 2017, Besponsa (Pfizer) was approved by the FDA;

In 2017, Mylotarg (Pfizer) re-listed;

In 2019, three ADC drugs, Polivy (Roche), Padcev (Seagen and Astellas), and Enhertu (Daiichi Sankyo and AstraZeneca), were approved by the FDA;

In 2020, Trodelvy (Gilead) and Blenrep (GlaxoSmithKline) were approved by the FDA;

In 2021, Zynlonta (ADC Therapeutics) and Aidixi (Rongchang Biotechnology) were approved;

...